Okay, let's tackle this question about the first biologic agent approved for psoriasis. First, I need to recall the history of biologics in psoriasis treatment. I remember that biologics target specific parts of the immune system involved in the disease process. The question is asking for the first one approved by the FDA.

Hmm, the options aren't listed here, but common biologics for psoriasis include TNF-alpha inhibitors like etanercept, adalimumab, and infliximab. There's also IL-12/23 inhibitors like ustekinumab and IL-17 inhibitors like secukinumab. Now, which one was first? I think etanercept was one of the earliest. Let me check my memory. Etanercept was approved in 1996 for rheumatoid arthritis, but when was it approved for psoriasis? I believe it was approved for psoriasis in 2002. Then adalimumab came later. So the first biologic for psoriasis would be etanercept.

Wait, but I should confirm if there were any others before that. For example, maybe a different class? Oh, the first biologic for psoriasis was actually etanercept in 2002. So if the options include etanercept, then that's the correct answer. Let's make sure there's no confusion with other drugs. The user's correct answer is option A, which would be etanercept. So the explanation should highlight that etanercept was the first FDA-approved biologic for psoriasis, acting as a TNF-alpha inhibitor. The other options would be other biologics approved later. The clinical pearl here is to remember that TNF-alpha inhibitors were the first class used for psoriasis, with etanercept being the first among them.

**Core Concept**
Biologic agents target specific immune pathways in psoriasis, such as TNF-α, IL-17, or IL-23. The **first biologic approved** for psoriasis by the US FDA marked a shift from systemic therapies like methotrexate to targeted immunomodulation.

**Why the Correct Answer is Right**
**Etanercept** (a TNF-α inhibitor) was approved in **2002** for moderate-to-severe plaque psoriasis. It binds soluble and transmembrane TNF-α, blocking its interaction with receptors and reducing inflammation. This mechanism addresses the central role of TNF-α in psoriatic immune dysregulation and keratinocyte hyperproliferation.

**Why Each Wrong Option is Incorrect**
**Option A:** Adalimumab (another TNF-α inhibitor) was approved later in 2008 for psoriasis.
**Option B:** Ustekinumab (anti-IL-12/23) was approved in 2009, after etanercept.
**Option C:** Secukinumab (anti-IL-17A) gained approval in 2015, representing a newer biologic class.

**Clinical Pearl / High-Yield Fact**
**"Etanercept = First biologic for psoriasis (2002)"** – Remember TNF-α inhibitors were

✓ Correct Answer: A. Alefacept